ABOS: acumenpharm.com Expected earnings per share growth for next year
High trial failure risks and a lack of profitability at Acumen Pharmaceuticals (ABOS) are offset by patents for unique antibodies. Next year's EPS outlook clearly demonstrates this struggle, where 51.30 determines this parameter level. Geopolitical tensions complete the picture, hindering international research and disrupting the supply of chemical components essential for developing Alzheimer's disease therapy.
Analytical breakdowns and data insights for company acumenpharm.com (ABOS)
- price and consensus price forecast:
- market capitalization information:
- book capitalization information:
- company total debt and liquidity indicators:
Total Debt to Capital Acumen Pharmaceuticals|ABOS - Long-Term Debt to Capital|Short-Term Debt to Equity Acumen Pharmaceuticals, Inc.|ABOS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Acumen Pharmaceuticals|ABOS - Company Long-Term Liabilities|Company Short-Term Debts Acumen Pharmaceuticals|Quick Ratio acumenpharm.com
- net income and valuation ratios data:
ABOS - Net Income|Projected Future Earnings Acumen Pharmaceuticals|ABOS - Market Cap to Earnings|Projected Price to Earnings Acumen Pharmaceuticals|ABOS - PEG Multiple|Enterprise Value to EBITDA Ratio Acumen Pharmaceuticals|ABOS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Acumen Pharmaceuticals|ABOS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth acumenpharm.com|ABOS - Net earnings per share growth this year|Earnings growth forecast for next year Acumen Pharmaceuticals
Fundamental company valuation:ABOS, Acumen Pharma
This indicator measures the weighted average change in analyst earnings per share (EPS) forecasts, neutralizing the time lag associated with quarterly reporting. By analyzing the history of EPS expectation shifts, an investor can determine the speed of capital flow and the risk of asset overheating. For Acumen Pharmaceuticals (ABOS), this price action reflects the market's assessment of the rigor of management's clinical trials in Alzheimer's disease therapy.
Analysis of competing companies
Net earnings per share growth forecast for next year Biogen Corp|Projected earnings per share growth rate for next year NBIX (Neurocrine Corp)|Expected earnings per share growth for next year RGC (Regencell Bioscience)|AXSM (axsome.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals Inc. ACAD|XENE (Xenon Pharmaceuticals Inc.) - Net earnings per share change forecast for next year|Viking Pharma - Earnings growth forecast for next year|Expected earnings per share trend next year SUPN (Supernus Corp)|CPRX: Earnings growth forecast for next year|denalitherapeutics.com (DNLI) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Harmony Biosciences Holdings, Inc.|BHVN: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Amylyx (AMLX)|Expected earnings per share growth for next year Trevi Corp TRVI|Earnings growth forecast for next year PRAX (Praxis Precision Medicines)|Earnings growth forecast for next year anavex.com AVXL|CeriBell - Earnings growth forecast for next year|Prothena Corporation plc (PRTA) - Expected earnings per share growth for next year|ALEC: Earnings growth forecast for next year|Expected net earnings per share growth next year Annexon Biosciences Inc. (ANNX)|Expected earnings per share growth for next year OMER|Earnings growth forecast for next year neurogene.com|Expected earnings per share growth for next year ACIU (AC Immune SA)|Projected earnings per share increase next year VYGR|Earnings growth forecast for next year NMRA (Neumora Therapeutics Inc)|Consensus forecast of earnings per share growth for next year Scilex Holding Company, Inc. (SCLX)|Tevogen Bio Holdings - Earnings growth forecast for next year|Alpha Cognition (ACOG) - Expected earnings per share growth for next year|CGTX: Earnings growth forecast for next year|Inhibikase Therapeutics Inc (IKT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Cassava|Net earnings per share growth forecast for next year ASRT|Net earnings per share growth forecast for next year Coya Therapeutics, Inc. (COYA)|Consensus forecast of earnings per share growth for next year vistagen.com|Earnings growth forecast for next year OVID (Ovid Therapeutics)|Earnings growth forecast for next year CervoMed, Inc. CRVO|Alterity Therapeutics Ltd - Earnings growth forecast for next year|CLNN: Net earnings per share growth forecast for next year|pepgen.com (PEPG) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Jupiter Neurosciences, Inc. (JUNS)|Net earnings per share growth forecast for next year Relmada Therapeutics, Inc.|Annovis Bio Inc (ANVS) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Grace Therapeutics, Inc. (GRCE)|Firefly Neuro - Projected earnings per share growth rate for next year|Earnings growth forecast for next year KLTO (Klotho Neurosciences)|NeuroSense Therapeutics Ltd (NRSN) - Expected net earnings per share growth next year|RVPH: Expected earnings per share growth for next year|MTVA - Earnings growth forecast for next year|NeurAxis, Inc (NRXS) - Net earnings per share growth forecast for next year|Helius Medical Technologies - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Passage Bio Inc.|Expected net earnings per share growth next year Neuphoria NEUP|Earnings growth forecast for next year NERV|Earnings growth forecast for next year Athira Pharma Inc (ATHA)|Earnings growth forecast for next year ADXN (Addex Therapeutics, Ltd.)|ALZN - Expected earnings per share growth for next year|CYCN: Expected earnings per share growth for next year|PTIX - Earnings growth forecast for next year|pasitheaclinics.com (KTTA) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Cortigent|ATXI (Avenue Therapeutics, Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year BrainStorm Cell Therapeutics Inc. BCLI|Net earnings per share growth forecast for next year Cara Therapeutics, Inc. (CARA)|chromocell.com - Projected earnings per share growth rate for next year|Eliem Therapeutics Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year ITCI|LBPH - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year MRNS|NKGN: Earnings growth forecast for next year|neurobopharma.com - Expected earnings per share trend next year|SAGE (Sage Therapeutics) - Earnings growth forecast for next year|Earnings growth forecast for next year Synaptogenix Inc.|Net earnings per share growth forecast for next year Trevena, Inc (TRVN)|VIGL (vigilneuro.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Anew Medical WENA|CERE - Expected earnings per share growth for next year
